 AGOURA HILLS, California, Jan. 13, 2021 GLOBE NEWSWIRE -- Mateon Therapeutics, Inc. OTCQB: MATN Mateon, a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19. 